Lundbeck has received the US FDA fast track designation for amlenetug, a potential treatment for multiple system atrophy (MSA ...

H. Lundbeck A/S (Lundbeck) today announced that amlenetug has received Fast Track designation from the United States (US) Food and Drug Administration (FDA).

The FDA has granted Fast Track Designation to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA).

Lundbeck’s total revenue grew by +14% at constant exchange rates (CER) and 11% in kroner terms to 22,004 million kroner ...

The FDA has granted Fast Track Designation to Lundbeck’s investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA).

Alpha-synuclein inhibitors are a class of investigational therapies targeting the pathological aggregation of alpha-synuclein, a protein implicated in neurodegenerative diseases like Parkinson's ...

H. Lundbeck A/S (Lundbeck) announces that, after 12 years of dedicated service on Lundbeck’s Board of Directors, Lars Søren Rasmussen has informed his decision not to seek re-election at the Annual ...

Amlenetug received Orphan Drug Designation (ODD) from the US FDA in April 2024, the EMA in May 2021 and SAKIGAKE designation ...

Alzheimer's Disease Clinical Trial Pipeline Major pharmaceutical companies are working to advance the pipeline space and unlock the future ...

Investing.com -- Shares of Lundbeck dropped by 7% following the release of its fourth-quarter financial results, which revealed revenues falling short of consensus estimates. The Danish pharmaceutical ...

Recognizing Siegel’s importance as an employee and a respected figure among Israeli psychiatrists, Lundbeck Global took ...